Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salbutamol inhalation with rapid deep breathing versus standard inhalation in acute obstructive airway disease
IRCT20171231038154N1Phase 3Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of salbutamol in asthma, chronic obstructive pulmonary disease (COPD) and bronchoconstriction (2 arms), sponsored by Shahid Sadoughi University of Medical Sciences. Primary endpoints: Peak expiratory flow at 5 minutes, Peak expiratory flow at 10 minutes and 2 more. Started Jun 2018; status: completed.
02
Drugs
salbutamol
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)bronchoconstriction
Beyond the preview
Go deeper on IRCT20171231038154N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20171231038154N1.